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Abstract
 OBJECTIVE—To determine the feasibility of a detailed pain sensitivity assessment using body 
wide musculoskeletal tender points (TPs) in women with different types of chronic pelvic pain 
(CPP) and compare phenotypic differences.
 METHODS—Seventy women with CPP and 35 healthy women underwent musculoskeletal 
evaluation of TPs in the pelvic floor, abdomen, groin, inner thigh, and all 18 fibromyalgia (FM) 
TPs. Subjects scored elicited pain on a numeric rating scale (NRS). Tender point pain scores were 
used for intergroup comparison and intragroup correlation.
 RESULTS—Women with CPP were grouped as having either bladder pain syndrome (BPS, 
n=24) or myofascial pelvic pain (MPP, n=11) singularly or both concomitantly (BPS+MPP, n=35). 
Tender point pain scores for all evaluations were higher in women with CPP compared to healthy 
women (p<0.001). Women with BPS+MPP had elevated TP pain for each evaluation compared to 
women with BPS alone. Pelvic floor and FM TP scores correlated strongly in the MPP group, 
moderately in the BPS+MPP group, and weakly in the BPS alone group. While some moderate 
and strong correlations between different body locations were present in all three groups, only the 
BPS+MPP group showed moderate to strong correlations between all body TPs.
 CONCLUSIONS—Detailed musculoskeletal evaluation of women with CPP is feasible and 
well tolerated. Careful phenotyping differentiated BPS, MPP, and BPS+MPP groups. Attending to 
the differences between these groups clinically may lead to more effective treatment strategies and 
improved outcomes for patients with CPP.
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 INTRODUCTION
Chronic pelvic pain (CPP) affects as many as 15% of women in the United States at some 
time in their lives, with annual medical costs estimated at $2.8 billion (U.S.) in 1996.1,2 CPP 
is characterized as persistent pain in the pelvic region perceived to arise from the 
gynecologic, urologic, gastrointestinal, and/or musculoskeletal systems. Common and 
frequently coexisting CPP conditions include myofascial pelvic pain (MPP) and bladder 
pain syndrome (BPS). Typically presenting with symptoms of dyspareunia or lower 
abdominal pelvic pain, women with MPP have myofascial tender points (TPs) in the 
muscles of the pelvic floor upon physical examination. BPS is a chronic idiopathic visceral 
pain syndrome with symptoms of chronic (>6 months) pelvic pain featuring pressure or 
discomfort related to urinary bladder fullness and persistent urinary urgency or frequency.3
The high prevalence (78–87%) of concomitant myofascial pain, frequently extending 
beyond the anatomical boundaries of the pelvis in women with BPS,4,5 suggests these two 
disorders may share a common pathophysiology. Additionally, almost a quarter of women 
with CPP have musculoskeletal abnormalities,6 yet comprehensive musculoskeletal 
examination is seldom considered during medical evaluation.7,8 One might conceive several 
ways for muscle to become painful in patients with BPS. Muscle involvement could occur in 
response to bladder inflammation in a type of visceral or cross-organ somatic co-
sensitization.9 Muscle could also constitute the primary source of pain and entrain changes 
in bladder function.10,11 Finally, both muscle and bladder could reflect a third deeper 
pathophysiologic change, such as a neural network alteration or an immunologic process. 
These and other mechanisms could also occur in combination or differ across individuals. 
Consensus guidelines for the management of CPP created in 2005 highlighted the need for a 
better understanding of myofascial dysfunction.12 Although body-pain mapping based on 
pain symptom questionnaires has revealed multiple complaints in other body locations in 
women with BPS,13 there is clear need to establish an objective, standardized 
musculoskeletal evaluation in women with CPP.
Our overarching hypothesis is that detailed examination of musculoskeletal pain sensitivity 
in different anatomic regions in patients with CPP can help to classify patients into 
potentially meaningful distinct subgroups. For example, involvement of body areas far 
removed from the pelvis suggests a generalized abnormality of central nervous system 
processing, whereas more restricted involvement of regions near the pelvis might imply 
more local changes. The present study aimed to 1) determine the feasibility of a detailed 
pain sensitivity assessment using musculoskeletal TPs in various body locations in women 
with CPP; and 2) compare possible phenotypic differences and correlations between body 
locations in patients with MPP or BPS to healthy controls (HC) to generate hypotheses 
regarding their pathophysiology.
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 MATERIALS AND METHODS
This study was approved by the University Hospitals Case Medical Center (UHCMC) 
Institutional Review Board (Cleveland, Ohio). Women (18–78 years) with CPP and healthy 
controls consented for participation in this study (2011/02 – 2014/01), part of the Interstitial 
Cystitis: Elucidation of Psychophysiologic and Autonomic Characteristics study (ICEPAC; 
ClinicalTrials.gov Identifier: NCT01616992). ICEPAC is a comprehensive, interdisciplinary 
approach to evaluation of women with MPP and BPS. The multidisciplinary team 
conducting the study consisted of a psychologist, urologist, gynecologist, urogynecologist, 
anesthesiologist, and neurologist. Specific details and methods of the study have been 
published.14 In summary, women with BPS, MPP, BPS+MPP, and healthy controls 
underwent detailed examination to elucidate the role of central and peripheral nervous 
system processing in CPP. The evaluation consisted of a structured neurologic examination 
of limbs and pelvis, tender point examination, autonomic testing, electrogastrography, and 
assessment of comorbid functional dysautonomias, assessments of stress and response to it, 
trauma history, and general psychological function. All subjects also underwent detailed 
assessment of pelvic pain symptoms, voiding patterns, gynecologic history, prior and current 
treatments, and present comorbidities. The primary aim of the work presented herein was to 
determine the feasibility and utility of a detailed pain sensitivity assessment using body wide 
musculoskeletal TPs examination in women with different types of CPP and compare 
phenotypic differences of whole body TP assessment among the groups. The primary 
outcome was a TP pain assessment based on a standardized numeric rating scale (NRS) pain 
score, with 0 meaning “pressure only” and 10 defined as “worst pain imaginable”.
Subjects were recruited from clinical practices and pelvic pain clinic. Additionally, we 
advertised the study through the Interstitial Cystitis Association and Interstitial Cystitis 
Network. Subjects were enrolled and categorized into one of the groups according to study 
definitions for each group when our screening evaluation confirmed the inclusion criteria. 
Subject screening included a pelvic floor examination and assessment of bladder pain 
symptoms. With the exception of a few subjects recruited from an examiner’s own clinic, 
examiners were unaware of pelvic pain phenotype prior to examination with the results of 
examinations leading to subject grouping. Inclusion criteria for study and subject 
classification were based on recommendations from our advisory board and evidence from 
available literature. Currently, there is no accepted definition or standardized means of 
examination for the presence of MPP.15 We included subjects into the MPP group when they 
reported at least 3 months of non-cyclic CPP unrelated to bladder filling or emptying and a 
minimum NRS pain score of at least 4 out of 10 using 2kg pressure applied with the index 
finger onto at least 2 of 5 examined pelvic floor TPs. Pelvic floor TPs included bilateral 
levator ani (puborectalis) and obturator internus muscles and a single midline perineal 
assessment (Figure 1). We used the modified assessment validated by Zolnoun et al.11 
Initially, a pelvic muscle algometer was used for training purposes under direct supervision 
of Dr. Zolnoun. This algometer has a pressure sensor capable of measuring a wide spectrum 
of force and allows direct and isolated palpation of pelvic floor musculature. Investigators 
practiced placing the desired pressure on the pelvic musculature using paid, healthy 
volunteers. After training, the examination of subjects was performed without using the 
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pressure sensor. Pressure was standardized against an algometer before each examination. 
Subjects were included in the BPS group when they complained of at least 6 months of 
urgency, frequency, and bladder pain clearly linked to bladder filling and emptying in 
accordance with 2008 European Society for the Study of Painful Bladder Syndrome 
recommendations.3 Pelvic TPs played no role in this definition. Since a large proportion of 
participants met criteria for both chronic pelvic pain disorders, they were classified as BPS
+MPP. Healthy controls were included when they had no history, symptoms or signs of 
fibromyalgia, chronic fatigue syndrome, BPS, MPP, CPP, migraine headache, or any other 
putative BPS comorbid disorders and be age matched to within ±3 years of a BPS+MPP 
subject. The exclusion criteria are presented in Table 1.
Additional pelvic adjacent and body-wide TP pain assessments were conducted using 
specific pressures applied with an algometer, except where indicated, so that pressure could 
be directly monitored during assessments. Abdominal exam (10 TPs) included 3kg pressure 
applied to rectus muscle midline (raphe) and lateral border muscle points (Figure 2). 
Palpation of the rectus muscles required the subject to actively lift their head while in the 
supine position. Inguinal ligaments (6 TPs total) were palpated bilaterally (3kg) along their 
length including origin, midpoint, and insertion (Figure 2).16 Inner thigh evaluation (6 TPs 
total) included bilateral (3kg) pain assessment in distal, mid-, and proximal inner thigh 
(Figure 2). Eighteen Fibromyalgia (FM) TPs, as described by the American College of 
Rheumatology,17 were palpated with the thumb using 4kg of pressure. While exerted 
pressure during the examination differed between body locations, we chose to apply the 
amount of pressure according to protocols that had been already published in the literature 
(4kg for FM, 3 kg for abdominal and inguinal TPs).16,17 Our advisory board recommended a 
2kg pressure for pelvic muscle evaluation as there was a concern of examination tolerance in 
the context of myofascial pain.
Data were analyzed as follows. Age and BMI were compared using one-way ANOVA 
followed by Tukey’s multiple comparisons test (GraphPad Prism v6.1, GraphPad Software, 
La Jolla, California). A final “TP pain score” was defined for each examination as the 
average of all TPs for that subject, i.e. averages of pelvic floor, abdominal, inguinal, thigh or 
FM TPs. Group mean TP scores were compared using the Mann-Whitney U test and 
pairwise group TP score correlations and 95% confidence intervals between regions were 
calculated in R18 using the TP score and the logarithm of (TP score + 1). Pairwise group TP 
score correlations, using the TP score and the logarithm of (TP score + 1) were also 
calculated. Since the BPS group was significantly older than the other 3 groups, we utilized 
a generalized linear model (GEE) to evaluate age as a significant predictor of the pain TP 
scores in all five locations (pelvic floor, FM, groin, inner thighs, and abdomen). Correlations 
were considered to be weak, moderate and strong with r <0.3, 0.3 < r > 0.6, and r >0.6, 
respectively. After screening, all subjects completed the Multidimensional Pain Inventory 
(MPI),19 a comprehensive measure of pain, function and coping.20 This questionnaire served 
as a covariate in the analysis to determine the impact of higher pain levels on pain 
correlations across body regions.
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 RESULTS
Following a screening exam for subject distribution based on pelvic pain, 105 women were 
grouped as follows: 11 MPP, 24 BPS, 35 BPS+MPP, and 35 HC. As shown in Table 2, 
women with BPS alone tended to be older (F(3, 101) = 4.513, p<0.05) than other groups, 
whereas BMI was similar (F(3,101) = 2.012, NS).
Mean TP scores in healthy control women were lower (Figure 3, p<0.001, all comparisons) 
than in CPP subjects, whereas TP scores did not differ between women with MPP and those 
with BPS+MPP. By definition, women with MPP (MPP or BPS+MPP) had high pelvic floor 
TP pain, leading to significantly higher mean pelvic floor TP scores (p<0.001) than did 
women with BPS alone. FM TP scores were 2.2±1.8 (SD) in subjects with BPS alone as 
compared to 3.7±2.4 in BPS+MPP (p<0.05) and 3.9±2.4 in MPP (p=0.05) (Appendix A). 
While women with BPS or MPP alone had elevated inguinal, inner thigh, and abdominal TP 
scores compared to control, there was no difference between these two pain groups (p>0.05). 
The combined group (BPS+MPP) had significantly more pain in every location than did 
subjects with BPS alone. In the GEE model, age was not in any model for TP scores in the 
five locations.
Pairwise correlations and 95% confidence intervals of pelvic floor TP scores and those of 
FM, inguinal, inner thigh, and abdomen are shown in Table 3. Data revealed a strong 
positive correlation (r= 0.68, 95% CI 0.13 – 0.91) between pelvic floor and FM TP score for 
subjects with MPP compared to a moderate (r= 0.36, 95% CI 0.03 – 0.61) correlation for 
subjects with BPS+MPP. No correlation between pelvic floor and FM was found in subjects 
with BPS without MPP (r= −0.18, 95% CI −0.54 – 0.24). Other correlations with the pelvic 
floor in BPS subjects were weak as well. Moderate positive correlations between pelvic 
floor TP scores and other body regions were found in women with BPS+MPP. Owing to the 
smaller sample size, the correlations for MPP alone have much larger confidence intervals. 
Including MPI scores in the analysis as a covariate did not alter the correlations, suggesting 
that these did not simply reflect overall higher pain levels in women with BPS+MPP.
Pairwise correlations of TP scores for all other body regions are shown in Table 4. Data 
revealed moderate to strong positive correlations for TP scores between all body regions in 
the BPS+MPP group. The highest positive correlations were found between inguinal and 
abdominal TP regions in all three CPP groups.
 DISCUSSION
Several findings from this study emerged. First, we were able to complete a structured 
musculoskeletal examination of TPs in various body locations in all study subjects. This 
examination was feasible, tolerated by the patients, and provided a measure of deep tissue 
pain sensitivity in women with CPP. Second, women with CPP had significantly higher TP 
pain scores on musculoskeletal evaluation for all tested body regions when compared to HC. 
Third, careful phenotyping of women with CPP demonstrated differences in CPP subtypes, 
including subjects with BPS alone, MPP alone, or both BPS and MPP together. Greater pain 
levels occurred in all body regions when BPS and MPP were present concomitantly. While 
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some moderate and strong correlations between different body location TPs were seen in all 
groups, only this BPS+MPP group consistently showed moderate to strong correlations 
between all body TPs, suggesting central sensitization as a more prominent feature in this 
group than in those with BPS alone.
This study reports on tender, not trigger, point assessment in CPP. Tender points are defined 
as areas of tenderness occurring in the muscle, muscle-tendon junction, bursa, or fat pad.21 
As opposed to tender points, myofascial trigger points are characterized by point tenderness 
on a taut muscle band, local twitch response, referred pain in a different location reproduced 
by palpation of the trigger point, and restricted range of motion.22,23 MPP is not well 
defined in the existing literature. The frequent use of the terms “tender point” and “trigger 
point” interchangeably further complicates the definition of MPP. Given the prevalence of 
MPP in women, it would seem important to develop diagnostic criteria for this disorder. 
Based on available literature and our prior work,11 we propose that MPP criteria include the 
following: 1) spontaneous chronic lower abdominal and/or pelvic pain for 3 months or more; 
2) pain worsened by stretching or pressure upon the pelvic muscles (e.g. insertion of a 
tampon, a speculum, or intercourse); 3) tenderness upon palpation (2 Kg of pressure; 
“moderate pressure” in a clinical setting) of at least 2 well identified pelvic floor muscles 
with a NRS of 4 or more on a zero to ten scale. The pelvic floor musculoskeletal 
examination did not extend the duration of the standard pelvic examination by more than a 
minute or two in our study. The presence or absence of another CPP disorder such as 
vulvodynia, endometriosis or BPS does not conceptually influence the diagnosis of MPP, 
which may or may not be related to these other disorders. This definition has the advantage 
of simplicity and provides a relatively uniform basis for comparing patients with additional 
CPP diagnoses independently of one another.
When defining MPP in this way, several properties of this syndrome emerge when compared 
to BPS. First, MPP is associated with higher tender point pain scores in most areas of the 
body. Second, the correlation of pelvic floor TPs with FM TPs is moderate to strong (Table 
4) and persists even when accounting for overall pain level, suggesting that a central driver 
for TPs may be present in MPP with or without concomitant BPS. Third, the highest TP pain 
scores occurred in the BPS+MPP group for inguinal, inner thigh, and abdominal TPs, but 
not for FM TPs. This more localized finding is consistent with a viscero-viscero-somatic 
hyperalgesia phenomenon where co-existing algogenic conditions in two internal organs in 
the same patient (bladder and muscle) enhance pain symptoms.24 Although our findings are 
consistent with the previously reported high prevalence of levator muscle pain in women 
with bladder pain,4,5 prior reports did not provide the same broad whole-body perspective by 
comparing TP’s in other body locations. Tripp et al implicitly considered BPS a subset of a 
more generalized pain disorder, but did not distinguish the subset with MPP.13 Using the 
symptom-based O’Leary Sant Patient Questionnaire to diagnose BPS,25 the authors found 
that subjects with BPS reported more pain complaints in the thighs, abdominal region, back, 
and the posterior surface of the head compared to healthy control subjects. Since this 
questionnaire did not consider MPP and the study did not involve musculoskeletal 
examination, the distinction between the two disorders could not be evaluated. Thus, our 
findings extend and refine Tripp’s concepts by including more precise phenotypic 
information and a clinical examination that delineates three separate pelvic pain sub-groups.
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The difference in TP pain severity between BPS and MPP (+/− BPS) groups may have 
several explanations. Some of these differences are clearly definitional based on study 
defined criteria. However, the lower TP scores for the FM examination in the BPS only 
group and the absence of a relationship between TP in the pelvis and FM body examination 
suggest some fundamental differences between BPS and MPP. The development of MPP in 
the context of BPS may signal the onset of central sensitization that is not present in isolated 
BPS, or may reflect difference in susceptibility to pain. Longitudinal studies will be required 
to determine if such an evolution occurs or if the phenotypic distinctions remain constant 
throughout the life of the disorders. If the advent of MPP signals central sensitization, one 
would predict greater generalized hyperalgesia in this patient group. Several reports describe 
decreased pain threshold (increased generalized hyperalgesia) or central sensitization with 
altered pain control in response to stimuli in different body locations in women with CPP 
with unknown MPP status.26–30 Lai et al found the presence of segmental hyperalgesia 
(suprapubic area) in the subjects with BPS without FM tender points as compared to age 
matched healthy controls.27 The reduction of pain thresholds in chronic musculoskeletal 
(including low back) pain suggests generalized hypersensitivity.26 Thus, if myofascial pain 
reflects reduction in pain threshold, it may drive or reflect central hyperalgesia and altered 
responses to pain stimuli in women with BPS.
The cause of the body-wide TPs remains unclear. Because they occur so diffusely, one may 
reasonably presume dysfunction of central nervous system pathways responsible for pain 
modulation. However, it is possible that pelvic TPs prime other potential TPs in some way. 
Testing this hypothesis would require retesting whole body TPs after the pelvic TPs have 
resolved, for example after an effective course of pelvic floor physical therapy. At this stage, 
the meaning of these body-wide TPs remains unclear from a treatment perspective as well. 
However, our findings do point to the utility of examining patients with CPP for diffuse 
body TPs as that knowledge will likely affect clinical decision making.
This study has several limitations. The subgroup consisting of women with only MPP is 
small and important differences in this group may not be readily apparent. Given the lack of 
previously defined clinical criteria for MPP, the criteria proposed herein may require further 
refinement. Our study protocol allowed participants to continue their pain medication 
treatment regimen to optimize recruitment. While this approach may have impacted pain 
measurements, it does not differentiate the groups and represents “real life”, reproducible 
assessment of CPP. Examination methodologies were standardized by our study advisory 
board and investigators. Applied pressure to different body locations differed as we 
combined the protocols evaluating myofascial pain from different published protocols. 
Multiple investigators performed examinations and, as such, data could be subject to 
examiner bias. Although a single neurologist with expertise in pain quantification trained all 
examiners, inter-examiner reliability was not evaluated. Finally, our cross-sectional study 
design does not allow any inference regarding the critical questions of causation and 
chronology - does bladder pain lead to tender points or vice-versa, etc. Cross-sectional 
design also limits our assessment of true duration of pain because of recall bias. We selected 
the abdominal and adductor muscle points because they are muscular and therefore similar 
to the pelvic muscle tender points, while the inguinal points are tendinous, and therefore 
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more similar to the fibromyalgia points which frequently occur in tendinous insertion areas. 
We do not know whether these are different or not from a pathophysiologic perspective.
Data presented herein underscore the importance of a broad musculoskeletal TP evaluation. 
Based on our study, musculoskeletal evaluation of women with CPP is feasible, well 
tolerated by patients, and could be performed by a general obstetrician-gynecologist or 
specialist when evaluating women with CPP. If co-existing myofascial pain sensitivity (a 
possible sign of sensitization) is detected in patients diagnosed with BPS, the provider may 
want to consider approaches beyond those focused on the bladder or pelvic floor, such as 
whole body physical therapy, exercise programs designed to promote physical 
reconditioning, or other evidence-based approaches to treating generalized pain syndromes 
such as cognitive behavioral therapy or tricyclic agents.
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Figure 1. 
Image depicting the pelvic floor region as viewed from above with anterior being upward. 
The 5 shaded dots demonstrate the site of pressure application (2Kg with the examiner’s 
gloved index finger) in both oburator internus muscles, both levator ani muscles, and in the 
perineal body.
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Figure 2. 
Image depicting the abdominal (shaded circleres), inguinal (shaded stars) and thigh (shaded 
pentagons) tender point palpation sites. Pressure (3 Kg) was applied at each site using an 
algometer.
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Figure 3. 
Image depicting mean tender point scores in different body locations for all study groups.
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Table 1
Exclusion criteria for study participation
Exclusion Criteria
1. Any major surgical intervention with general anesthesia, pelvic surgery within the previous 120 days
2. Drug/medical device or non-invasive treatment initiation (such as bladder instillation or pelvic floor therapy) within 30 days
3. Intravesical therapy, botox or hydrodistention within 90 days
4. Previous augmentation cystoplasty, cystectomy or cytolysis, neurectomy (i.e., hypogastric nerve plexus ablation), implanted neural 
stimulator in active use
5. Pelvic, bladder neoplasm/infection, recurrent cystitis, hematuria not related to BPS
6. Evidence of unstable chronic medical conditions (e.g. liver impairment, poorly controlled cardiovascular, respiratory or endocrine 
function, uncontrolled psychiatric illness)
7. Neuropathy, central nervous system disorder (e.g., Parkinson’s Disease, Alzheimer’s, MS, stroke, etc)
8. Use of hormones (except insulin, thyroid replacement or oral contraceptives)
9. Current substance abuse, > 10 alcoholic beverages per week
10. Currently attempting to become pregnant, pregnant (confirmed by pregnancy test), breast feeding
11. Any condition that the physician deems would interfere with the subject’s ability to participate or which would clearly confound 
interpretation of study results
Additional Exclusion Criteria for Healthy Subjects
12. A diagnosis of BPS, MPP or chronic pelvic discomfort, or any chronic pain disorder of any type.
13. Fibromyalgia or Chronic Fatigue Syndrome.
14. Dysautonomias (e.g. Migraine Headaches, Complex Regional Pain Syndrome, Cyclic Vomiting) or a history of Psychiatric Disorders 
(e.g. Post-Traumatic Stress Disorder, Panic Disorder)
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Table 2
Demographics
BPS
(n=24)
MPP
(n=11)
BPS+MPP
(n=35)
HC
(n=35)
Age, years 48.5±14.1* 32.8±9.9 38.6±12.8 38.0±15.0
BMI 28.0±8.1 31.9±7.5 31.3±9.4 26.9±8.5
Race, n (%)
  Caucasian 22 (92) 7 (64) 25 (71) 25 (71)
  African-American 1 (4) 4 (36) 9 (26) 5 (14)
  Other 1 (4) 0 1 (3) 5 (14)
Values are mean ± SD where applicable.
*
BPS group is older than all other groups (p<0.05)
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Table 3
Pearson correlation coefficient and 95% confidence intervals of group mean tender point pain scores between 
the Pelvic Floor and other body areas.
FM Inguinal Inner Thigh Abdomen
BPS
−0.18 0.11 −0.01 0.06
(−0.54, 0.24) (−0.31, 0.49) (−0.41, 0.40) (−0.36, 0.45)
MPP
0.68 0.17 0.56 0.12
(0.13, 0.91) (−0.48, 0.70) (−0.06, 0.87) (−0.52, 0.67)
BPS+MPP
0.36 0.48 0.44 0.50
(0.03, 0.61) (0.18, 0.70) (0.12, 0.67) (0.20, 0.71)
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